Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Dicot Pharma

0.21 SEK-0.95 %18/11 17:29
Less than 1K followers

DICOT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-0.95 %
-7.14 %
-3.88 %
-0.48 %
-23.93 %
-39.19 %
+96.00 %
-37.19 %
-90.86 %

Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization. The company is based in Uppsala.

Read more
Market cap
721.49M SEK
Turnover
2.01M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/2
2027

Annual report '26

28/4
2027

Interim report Q1'27

4/5
2027

General meeting '27

Third party research2026-11-18 15:26

Dicot Pharma: Phase IIb gets underway - Edison

Dicot Pharma has initiated Part I of its Phase IIb study of LIB-01 in erectile dysfunction (ED) with the first patient screened at a US centre, marking an important step towards dose optimisation and broader clinical validation ahead of Phase III. Part...

Dicot Pharma
Press release2026-11-18 07:00

Dicot Pharma startar klinisk fas 2b-studie inom erektil dysfunktion

Dicot Pharma
Press release2026-11-18 07:00

Dicot Pharma initiates phase 2b clinical study in erectile dysfunction

Dicot Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release2026-11-10 08:00

Dicot Pharma presenterar på Aktiespararnas event Stora Aktiedagarna den 24 november

Dicot Pharma
Press release2026-11-10 08:00

Dicot Pharma presents at Aktiespararnas’ event Stora Aktiedagarna on November 24

Dicot Pharma
Regulatory press release2026-11-02 15:00

Valberedning utsedd för Dicot Pharma AB

Dicot Pharma
Regulatory press release2026-11-02 15:00

Nomination Committee appointed for Dicot Pharma AB

Dicot Pharma
Regulatory press release2026-10-28 08:00

Dicot Pharma presenterar delårsrapport för Q3 2026 och bjuder in till webbsändning

Dicot Pharma
Regulatory press release2026-10-28 08:00

Dicot Pharma presents interim report Q3 2026 and invites to a webcast

Dicot Pharma
Press release2026-10-26 09:00

Dicot Pharma får nytt patent i Europa för LIB-01

Dicot Pharma
Press release2026-10-26 09:00

Dicot Pharma receives new patent in Europe for LIB-01

Dicot Pharma
Press release2026-10-13 09:30

Dicot Pharmas LIB-01 väckte uppmärksamhet när ledande experter presenterade vid SMSNA

Dicot Pharma
Press release2026-10-13 09:30

Dicot Pharma’s LIB-01 attracted attention when leading experts presented at SMSNA

Dicot Pharma
Press release2026-10-07 14:00

Dicot Pharma bjuder in till en investerarpresentation den 13 oktober

Dicot Pharma
Press release2026-10-07 14:00

Dicot Pharma invites to an investor presentation on October 13

Dicot Pharma
Regulatory press release2026-08-20 08:00

Dicot Pharma presenterar delårsrapport för Q2 2026 och bjuder in till webbsändning

Dicot Pharma
Regulatory press release2026-08-20 08:00

Dicot Pharma presents interim report Q2 2026 and invites to a webcast

Dicot Pharma
Press release2026-08-19 08:30

Dicot Pharma: tre abstracts om LIB-01 utvalda för presentation på ledande konferens inom sexualmedicin

Dicot Pharma
Press release2026-08-19 08:30

Dicot Pharma: three abstracts on LIB-01 selected for presentation at leading sexual medicine conference

Dicot Pharma
Press release2026-08-17 09:10

Dicot Pharma lämnar in klinisk prövningsansökan för fas 2b-studie i EU

Dicot Pharma